Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesDiscontinued psychiatric drugs in 2008
Expert Opinion on Investigational Drugs, 09/21/09
Kirchhoff VD et al. – During the past several decades, neuropsychiatric agents have been one of the fastest growing classes of medicinal agents. This expansion is in part due to the increased recognition of the prevalence and burden of illness associated with disparate neuropsychiatric disorders, increased public awareness and possibly reduced stigma associated with mental illness, as well as extensive marketing of neuropsychiatric agents to healthcare providers. Most of the agents reviewed herein represent modifications and/or refinements of pre–existing agents and/or theoretical approaches.
Related Articles
Psychotropic Drug Use During Breastfeeding: A Review of the Evidence
Pediatrics, 10/01/09
Relevance Score: 71%
Effects of Aging on Pharmacokinetic and Pharmacodynamic Drug Processes
Journal of Psychosocial Nursing and Mental Health Services, 10/26/09
Relevance Score: 68%
Nursing home structure and association with agitation and use of psychotropic drugs in nursing home residents in three countries: Norway, Austria and England
International Journal of Geriatric Psychiatry, 10/16/09
Relevance Score: 65%
Special care units for dementia individuals with behavioural problems
Cochrane Reviews, 10/21/09
Relevance Score: 64%
Antiretroviral and Immunosuppressive Drug-Drug Interactions in Human Immunodeficiency Virus-Infected Liver and Kidney Transplant Recipients
Transplantation Proceedings, 11/20/09
Relevance Score: 48%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of Methylphenidate on Cerebral Glucose Metabolism in Patients With Impaired Consciousness After Acquired Brain Injury
Clinical Neuropharmacology, 12/07/09
Gabapentin Enacarbil in Restless Legs Syndrome: A Phase 2b, 2-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Clinical Neuropharmacology, 12/07/09
Bayer HealthCare Pharmaceuticals Inc. Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease
Bayer HealthCare Pharmaceuticals, 12/07/09
Sponsor
Article Search
Sponsor